At the 2022 American Society of Hematology (ASH) annual meeting, new results for Tecvayli (teclistamab) have been presented by US pharma giant Johnson & Johnson 12 December 2022
Long-suffering investors in bluebird bio had a rare reason for cheer as the company presented positive results for betibeglogene autotemcel (beti-cel) at the Am 13 December 2021
US pharma major Bristol Myers Squibb has announced the first disclosure of results from a prespecified interim analysis of the pivotal TRANSFORM study at the Am 13 December 2021
At the 63rd annual meeting of the American Society of Hematology (ASH), Swiss pharma giant Novartis (NOVN: VX) has announced new positive data for Scemblix (asc 13 December 2021
Virtually every drugmaker with a presence in hematology is preparing for their end-of-year attempt to impress physicians and investors with the best of their fr 10 December 2021
Fitusiran, an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia, has shown its efficacy in late-stage trials. 25 November 2021
The Johnson & Johnson subsidiary Janssen has presented new data from the Phase III ANDROMEDA study, which evaluated Darzalex Faspro (daratumumab and hyaluronida 8 December 2020
Gilead Sciences company Kite has announced results from the primary analysis of ZUMA-5, a Phase II study evaluating Yescarta (axicabtagene ciloleucel) in adults 7 December 2020
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.